| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $28,739,970 ) (Continued on the next page) |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F31DA062453 | The Impact of Perinatal Fentanyl on Dopamine Neuron Circuitry and Behavior | 002 | 1 | NIH | 12/12/2024 | $0 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21MD018107 | Identifying Structural Vulnerability Latent Classes Associated with the Health Outcomes of Latino Immigrant Men in Baltimore | 000 | 2 | NIH | 11/11/2024 | $186,303 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21HL172155 | Integration of Pharmacogenomics and Metabolomics in the Study of Antiplatelet Efficacy | 000 | 2 | NIH | 11/13/2024 | $116,625 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DC012564 | Usher Proteins in the Inner ear Structure and Function | 000 | 13 | NIH | 11/8/2024 | $569,580 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U4C49932 | Pediatric Mental Health Care Access Program | 05 | 2 | HRSA | 1/17/2025 | $699,622 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL162940 | Computational Modeling of Device-Induced Platelet Activation and Receptor Shedding Relevant to Thrombosis and Bleeding in Device-Assisted Circulation | 000 | 3 | NIH | 11/27/2024 | $461,563 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI172827 | Multi-Omics Characterization of Plasmodium Vivax Hypnozoites | 000 | 3 | NIH | 11/22/2024 | $688,160 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS122777 | Targeting mitochondrial Complex I in neonatal hypoxia-ischemia | 000 | 4 | NIH | 1/15/2025 | $461,115 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AA028070 | Synaptic Mechanisms of Nucleus Accumbens Disinhibition by Ethanol | 000 | 5 | NIH | 12/13/2024 | $449,314 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37MH080046 | Internal Dynamics of the Postsynaptic Density | 000 | 18 | NIH | 11/18/2024 | $789,536 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AR077563 | Molecular Determinants of Pigmentation (MDoP) | 000 | 4 | NIH | 12/5/2024 | $435,440 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UM1AI148689 | Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | 000 | 6 | NIH | 12/11/2024 | $617,961 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UM1AI148689 | Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | 000 | 6 | NIH | 12/11/2024 | $897,466 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AG091717 | Optimal Use of Enhanced Barrier Precautions in Nursing Homes to Prevent the Transmission of MDROs | 000 | 1 | NIH | 12/10/2024 | $427,625 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG070072 | Brain-selective estrogen therapy for menopausal hot flushes in an advanced translational animal model | 000 | 5 | NIH | 12/12/2024 | $503,765 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA298839 | Tumor-associated pDC (TApDC) in liver cancer with HIV infection | 000 | 1 | NIH | 12/5/2024 | $634,061 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI178839 | Subversion of Keratinocyte Function by a Tick Salivary Protein | 000 | 2 | NIH | 12/9/2024 | $194,375 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25DE032530 | Maryland Program in Dental Research Experience (D-REX) | 000 | 3 | NIH | 12/13/2024 | $135,000 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA271540 | Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC | 000 | 3 | NIH | 12/18/2024 | $539,293 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS120930 | Molecular basis for adenosine A3 receptor agonists in the treatment of migraine | 000 | 4 | NIH | 12/13/2024 | $425,628 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG081693 | Deep-Learning Enhanced ASL MRI For Early AD Assessment | 000 | 2 | NIH | 12/16/2024 | $687,135 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL166402 | Targeting a Defined Surgical Stress-Induced Inflammatory Pathway to Improve Peri-Operative Outcomes | 000 | 3 | NIH | 12/20/2024 | $503,935 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL171120 | High Mechanical Shear Stress-Induced Neutrophil Dysfunction in Mechanically Assisted Circulation | 000 | 2 | NIH | 12/18/2024 | $516,895 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI176333 | New roles of IFN-inducible OAS proteins in innate immune defense against bacterial infections | 001 | 3 | NIH | 12/19/2024 | $616,500 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA269995 | Nanotherapeutic enhancement of interstitial thermal therapy for glioblastoma | 000 | 3 | NIH | 11/20/2024 | $571,318 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA285468 | First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers | 000 | 2 | NIH | 11/15/2024 | $575,397 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA285468 | First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers | 001 | 2 | NIH | 11/20/2024 | $165,766 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U01FD007982 | Racial and Ethnic Minority Acceleration for Health Equity Consortium U01 | 001 | 2 | FDA | 11/26/2024 | $100,000 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD108705 | Intersection of the mTOR/p70S6K1 signaling and the HIPPO-Yap tissue organizer in neurulation and diabetic embryopathy | 000 | 3 | NIH | 11/22/2024 | $586,642 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS129502 | Role of reactive astrocytes in prion diseases | 000 | 3 | NIH | 11/15/2024 | $560,291 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL168775 | Airway epithelial cytoglobin regulates nitric oxide synthase and development of primary ciliary dyskinesia and situs inversus | 000 | 2 | NIH | 11/19/2024 | $627,856 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U01DC013817 | Cell Type Specific Transcriptional Cascades in Inner Ear Development | 000 | 10 | NIH | 11/26/2024 | $490,911 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG079854 | Methods to Test Biomarkers of Aging as Shared Determinants of Alzheimers Disease and Related Dementias and Physical Disability | 000 | 3 | NIH | 11/26/2024 | $653,435 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI183599 | Genomic surveillance for artemisinin resistance in Africa: moving beyond a candidate gene approach | 000 | 1 | NIH | 11/29/2024 | $776,905 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK130238 | Pharmacogenetics of the Response to a GLP1R Agonist | 000 | 4 | NIH | 11/25/2024 | $604,825 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA273216 | Targeting polo-like kinase 1 (PLK1) for treatment of small cell lung cancer | 002 | 4 | NIH | 12/9/2024 | $583,443 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI168192 | Mechanisms coordinating the local and systemic resistance to pathogens | 000 | 3 | NIH | 10/30/2024 | $578,188 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01MH129310 | Behavioral and neural mechanisms mediating social motivation in a rat model for ASD | 000 | 3 | NIH | 11/1/2024 | $436,018 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R35GM156369 | Conformational Dynamics and Regulatory Mechanisms in the KCNH Family of Ion Channels | 000 | 1 | NIH | 1/17/2025 | $427,625 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK133421 | Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis | 000 | 3 | NIH | 1/17/2025 | $485,056 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K24HL127301 | Mentoring in Translational Research in Interstitial Lung Diseases | 000 | 11 | NIH | 1/17/2025 | $113,963 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK074797 | Inter-organ signaling in heme metabolism and organismal homeostasis. | 000 | 14 | NIH | 12/31/2024 | $357,057 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL172364 | Modulating the resolution of angiogenesis and normalization of the vasculature for therapeutic benefit | 000 | 1 | NIH | 1/13/2025 | $549,665 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA290796 | An engineered prodrug for inhibition of cancer growth and metastasis | 000 | 1 | NIH | 1/3/2025 | $435,773 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21MH136412 | White Matter Plasticity in Schizophrenia | 000 | 1 | NIH | 12/23/2024 | $201,503 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21CA270591 | Dual inhibition of PARP and STAT3 as a novel therapeutic approach for triple-negative breast cancer | 000 | 2 | NIH | 1/14/2025 | $163,063 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K99DA060209 | Postpartum Neurobiological Sequelae of Prescription Opioid Use During Pregnancy | 000 | 2 | NIH | 1/15/2025 | $191,608 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37NS125632 | KPTN Loss and Megalencephaly: mTOR Activation as Therapeutic Target | 000 | 4 | NIH | 1/15/2025 | $326,002 |
| | 2025 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U24HL175772 | A consortium facilitation, coordination, and data management center for the HVP | 000 | 1 | NIH | 1/15/2025 | $3,000,337 |
|
